Skip to main content
Terug
AMBFF logo

Ambu A/S

Datakwaliteit: 100%
Overbought
AMBFF
OTC Healthcare Medical - Devices
€ 13,65
€ 0,00 (0,00%)
Marktkapitalisatie: 3,66B
Ook genoteerd als AMBBY OTC
Dagbereik
€ 13,00 € 13,65
52-Weeksbereik
€ 12,75 € 19,35
Volume
600
50D / 200D Gem.
€ 13,40 / € 14,32
Vorige Slotkoers
€ 13,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 6,0 0,4
P/B 0,6 2,9
ROE % 10,5 3,8
Net Margin % 10,1 3,9
Rev Growth 5Y % 10,7 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 10,70% annually over 5 years — strong growth
Earnings grew 158,66% over the past year
ROE of 10,46% — decent returns on equity
Debt/Equity of 0,09 — conservative balance sheet
Generating 672,72M in free cash flow
P/E of 6,02 — trading at a low valuation

Groei

Revenue Growth (5Y)
10,70%
Revenue (1Y)11,78%
Earnings (1Y)158,66%
FCF Growth (3Y)87,18%

Kwaliteit

Return on Equity
10,46%
ROIC8,93%
Net Margin10,09%
Op. Margin12,99%

Veiligheid

Debt / Equity
0,09
Current Ratio2,72
Interest Coverage26,13

Waardering

P/E Ratio
6,02
P/B Ratio0,61
EV/EBITDA4,27
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11,78% Revenue Growth (3Y) 12,34%
Earnings Growth (1Y) 158,66% Earnings Growth (3Y) 90,21%
Revenue Growth (5Y) 10,70% Earnings Growth (5Y) 25,25%
Profitability
Revenue (TTM) 6,03B Net Income (TTM) 607,84M
ROE 10,46% ROA 7,94%
Gross Margin 55,97% Operating Margin 12,99%
Net Margin 10,09% Free Cash Flow (TTM) 672,72M
ROIC 8,93% FCF Growth (3Y) 87,18%
Safety
Debt / Equity 0,09 Current Ratio 2,72
Interest Coverage 26,13 Dividend Yield 0,00%
Valuation
P/E Ratio 6,02 P/B Ratio 0,61
P/S Ratio 0,61 PEG Ratio 0,27
EV/EBITDA 4,27 Dividend Yield 0,00%
Market Cap 3,66B Enterprise Value 3,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,03B 5,39B 4,78B 4,44B 4,01B
Net Income 607,84M 235,00M 168,00M 93,00M 247,00M
EPS (Diluted) 2,28 0,88 0,64 0,37 0,98
Gross Profit 3,37B 3,20B 2,71B 2,55B 2,50B
Operating Income 782,51M 645,00M 302,00M -26,00M 340,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,66B 7,15B 6,86B 7,22B 5,74B
Total Liabilities 1,64B 1,56B 1,47B 2,95B 1,79B
Shareholders' Equity 6,02B 5,59B 5,39B 4,26B 3,95B
Total Debt 545,96M 558,00M 584,00M 1,85B 823,00M
Cash & Equivalents 864,35M 615,00M 157,00M 187,00M 64,00M
Current Assets 3,15B 2,64B 2,01B 2,30B 1,61B
Current Liabilities 1,16B 1,06B 942,00M 1,16B 980,00M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#747 of 1024
34
Custom Deep Value Investing (Seth Klarman)
#399 of 820
43
Growth Price/Sales Ratio Focus (Ken Fisher)
#280 of 616
38
Value Defensive Investing (Benjamin Graham)
#53 of 708
65

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026